Basic↦Quality and Risk↦Quality Management System (QMS)↦Critical to Quality
Was betrifft es? Warum ist das wichtig?
Clinical studies vary greatly in scope, complexity, and budget. Identifying Critical-to-Quality (CtoQ) factors, and the risks associated with these factors, are crucial to:
- Ensure efficiency by focusing on risks that are critical to achieving study objectives (i.e. study outcome/endpoint)
- Provide credible and scientifically valuable research results
Protecting the integrity of study quality factors is essential to:
- Protect study participants (e.g. participant rights and safety)
- Have reliable and interpretable study results
- Have confidence in ensuing study interpretation and decision(s) taken (e.g. publishing)
Once CtoQ factors are identified, risks that threaten their integrity are determined and decisions are taken whether to accept or mitigate risks (i.e. based on risk probability, detectability and impact).
As research progresses, investigational product (IMP / IMD) uncertainties may increase (e.g. safety, efficacy). Therefore, product knowledge during its development, requires that CtoQ factors and risks threatening their integrity must be identified and assessed on a continuous basis.
Was muss ich befolgen?
As a SP-INV during study design development:
- Seek input from a broad range of stakeholders (e.g. study population representatives, data manager, statistician)
- Identify and prioritize quality factors that are critical to the study (i.e. in the Monitoring Plan focus on aspects that are CtoQ)
- Identify risks threatening the integrity of CtoQ factors
- Implement risk control-measures that are proportionate to inherent risks, and the importance of the collected information
- Train applicable study staff on study identified CtoQ factors, risks threatening their integrity, and any planned risk control-measures
As a SP-INV, plan and define for study conduct how to:
- Monitor the integrity of CtoQ factors
- Control risks to CtoQ factors (i.e. control-measure adjustments may become necessary or new / unanticipated risks may arise)
- Aassess the efficacy and applicability of risk control-measures
- Retain oversight and document CtoQ management
Wo kann ich Hilfe anfordern?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
References
ICH GCP E6(R3) – see in particular guidelines
- 3.11.4.3 Monitoring plan and CtoQ
- 6.2 Factors critical to quality
- 7.3 Management of CtoQ factors
ICH E8(R1) – see in particular guidelines
- 3. Designing quality into clinical studies
- 3.1 Quality by design of clinical studies
- 3.2 Critical to quality factors
- 3.3 Approach to identify CtoQ factors